| Literature DB >> 32083128 |
T Indrielle-Kelly1,2, F Frühauf3, M Fanta3, A Burgetova4, D Lavu5, P Dundr6, D Cibula3, D Fischerova3.
Abstract
OBJECTIVES: The primary aim was to investigate the diagnostic accuracy of transvaginal ultrasound (TVS) and magnetic resonance imaging (MRI) in the mapping of deep pelvic endometriosis (DE) in a diseased population. The secondary aim was to offer first insights into the clinical applicability of the new International Deep Endometriosis Analysis group (IDEA) consensus for sonographic evaluation, which was also adapted for MRI and surgical reporting in this study.Entities:
Mesh:
Year: 2020 PMID: 32083128 PMCID: PMC7011347 DOI: 10.1155/2020/3583989
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Index tests methodology.
| Ultrasound | Magnetic resonance imaging | ||
|---|---|---|---|
| Technical parameters | Voluson E10 (GE medical Systems, Zipf, Austria) | 3 T MR scanner with phased-array pelvic coil (Skyra, Siemens AG, Erlangen, Germany) | |
| Standard gynecology setting | Slice thickness 3-4 mm with interslice gaps 0.0 mm–1.0 mm | ||
|
| |||
| Preparation | No bowel preparation or contrast gel sonography | Fasting for 4 hours | |
| Butylscopolamine 1 mg i.v. | |||
|
| |||
| Technical protocol (standardised for use in every participant) | Transvaginal ultrasound (TV probe 7–9 MHz) | Protocol-part 1 for pelvic DE location | |
| (1) 2D T2W sequences in sagittal, axial and oblique plane | |||
| Transabdominal ultrasound (curvilinear TA probe 4–7 MHz) | Protocol–part 2 for adnexal lesions | ||
| (2) Dixon technique 2D (T1W images incl. with and without fat suppression sequences)§ | |||
| (3) DWI in axial plane | |||
| (4) Postcontrast 2D T1W with fat suppression (i.v. gadolinium) | |||
|
| |||
| Imaged area | Pelvis | TVS | Whole pelvis from iliac crests to pubic bone |
| Upper urinary tract | TAS | T2-weighted sequences in coronal plane from symphysis up to kidneys | |
ESUR recommends 2D T2W sequences for pelvic DE [9]. §ESUR recommends 2D T1W sequences for endometriomas with Dixon technique as an alternative to confirm the presence of blood and to rule out a fat-containing lesion (such as dermoids) [9]. ESUR recommended as optional sequences for ‘indeterminate' adnexal endometriosis (differential diagnosis of pelvic inflammatory disease, malignancy) [9]. 2D, two-dimensional; DE, deep endometriosis; DWI, diffusion-weighted imaging; ESUR, European Society of Urogenital Radiology guidelines [9]; MRI, magnetic resonance imaging; T1W, T1 weighted; T2W, T2 weighted; i.v. intravenous; TAS, transabdominal ultrasound; TVS, transvaginal ultrasound.
Figure 1STARD Flow diagram. N; number of participants; TVS, transvaginal ultrasound; MRI, magnetic resonance imaging.
Baseline characteristics.
| Age (years), mean (SD) | 32.4 (5.3) | ||
|
| |||
| BMI, mean (SD) | 23.6 (3.9) | ||
|
| |||
| Parity, | Nulliparous | 32 (62.3) | |
| Uniparous | 13 (26.5) | ||
| Multiparous | 4 (8.2) | ||
|
| |||
| Fertility, | Primary infertility | 21 (42.9) | |
| Secondary infertility | 3 (6) | ||
| Normal fertility | 10 (20.4) | ||
| No reproductive attempts | 15 (31) | ||
|
| |||
| Hormonal treatment, | No treatment | 33 (67.4) | |
| Progestogen only | 12 (24.5) | ||
| Combined oral contraception | 4 (8.2) | ||
|
| |||
| Previous gynecological surgery investigating pain/infertility, | 0 | 25 (51) | |
| 1 | 20 (40.8) | ||
| 2 | 1 (2) | ||
| 3 | 3 (6) | ||
|
| |||
| Main symptoms, | Dysmenorrhea | 41 (83.8) | |
| Dyspareunia | 32 (62.3) | ||
| Dyschesia | 19 (38.8) | ||
| Noncyclical pain | 12 (24.5) | ||
| Dysuria | 8 (16.3) | ||
|
| |||
| Interval between initial symptoms experienced and diagnosis of endometriosis (years), mean (SD) | 2.4 (1.9) | ||
BMI, body mass index (kg/m2); n, number of participants; SD, standard deviation.
Cross tabulation of study results.
| Compartment | Areas investigated for DE | Index tests | TP (%) | FP (%) | TN (%) | FN (%) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | LR+ (95% CI) | LR− (95% CI) | Accuracy (95% CI) | p-value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anterior compartment | Bladder | TVS | 8 (16.3%) | 0 (0.0%) | 40 (81.6%) | 1 (2%) | 0.89 (0.52–1.00) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 0.98 (0.86–1.00) | Infinity | 0.11 (0.02–0.71) | 0.98 (0.89–1.00) | 0.25 |
| MRI | 9 (18.3%) | 2 (4.1%) | 38 (77.6%) | 0 (0.0%) | 1.00 (0.66–1.00) | 0.95 (0.83–0.99) | 0.82 (0.54–0.95) | 1.00 (1.00–1.00) | 20 (5.1–77.2) | 0.00 | 0.96 (0.86–0.99) | |||
| Ureteric obstruction by DE | TVS/TAS | 5 (10.2%) | 0 (0.0%) | 44 (89.8%) | 0 (0.0%) | 1.00 (0.48–1.0) | 1.00 (0.92–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | 1.000 | |
| MRI | 5 (10.2%) | 0 (0.0%) | 44 (89.8%) | 0 (0.0%) | 1.00 (0.48–1.0) | 1.00 (0.92–1.0) | 1.00 (1.00–1.00) | 100 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | |||
|
| ||||||||||||||
| Posterior compartment | USL§ | TVS | 25 (51%) | 5 (10.2%) | 10 (20.4%) | 9 (18.3%) | 0.74 (0.56–0.87) | 0.67 (0.38–0.88) | 0.83 (0.70–0.91) | 0.53 (0.36–0.68) | 2.21 (1.05–4.64) | 0.40 (0.20–0.77) | 0.71 (0.57–0.83) | 0.039 |
| MRI | 32 (65.3%) | 6 (12.2%) | 9 (18.3%) | 2 (4.1%) | 0.94 (0.80–0.99) | 0.60 (0.32–0.84) | 0.84 (0.74–0.91) | 0.82 (0.52–0.95) | 2.35 (1.26–4.40) | 0.10 (0.02–0.40) | 0.84 (0.70–0.93) | |||
| Right USL | TVS | 10 (20.4%) | 5 (10.2%) | 26 (53%) | 8 (16.3%) | 0.56 (0.31–0.78) | 0.84 (0.66–0.95) | 0.67 (0.45–0.83) | 0.76 (0.65–0.85) | 3.44 (1.40–8.50) | 0.53 (0.31–0.91) | 0.73 (0.59–0.85) | 0.001 | |
| MRI | 17 (34.7%) | 11 (22.4%) | 20 (40.8%) | 1 (2%) | 0.94 (0.73–1.00) | 0.65 (0.45–0.81) | 0.61 (0.49–0.72) | 0.95 (0.75–0.99) | 2.66 (1.63–4.33) | 0.09 (0.01–0.59) | 0.76 (0.61–0.87) | |||
| Left USL | TVS | 21 (42.9%) | 0 (0.0%) | 23 (46.9%) | 5 (10.2%) | 0.81 (0.61–0.93) | 1.00 (0.85–1.00) | 1.00 (1.00–1.00) | 0.82 (0.68–0.91) | 0.00 | 0.19 (0.09–0.42) | 0.90 (0.78–0.97) | 0.220 | |
| MRI | 23 (46.9%) | 2 (4.1%) | 21 (42.9%) | 3 (6.1%) | 0.88 (0.70–0.98) | 0.91 (0.72–0.99) | 0.92 (0.75–0.98) | 0.88 (0.71–0.95) | 10.17 (2.69–38.52) | 0.13 (0.04–0.37) | 0.90 (0.78–0.97) | |||
| Upper rectum | TVS | 10 (20.4%) | 0 (0.0%) | 39 (79.6%) | 0 (0.0%) | 1.00 (0.69–1.00) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | 1.000 | |
| MRI | 10 (20.4%) | 0 (0.0%) | 39 (79.6%) | 0 (0.0%) | 1.00 (0.66–0.89) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | |||
| Rectosigmoid | TVS | 16 (32.7%) | 5 (10.2%) | 27 (55.1%) | 1 (2%) | 0.94 (0.71–1.00) | 0.84 (0.67–0.95) | 0.76 (0.59–0.88) | 0.96 (0.80–0.99) | 6.20 (2.67–13.59) | 0.07 (0.01–0.47) | 0.88 (0.75–0.95) | 1.000 | |
| MRI | 16 (32.7%) | 5 (10.2%) | 27 (55.1%) | 1 (2%) | 0.94 (0.71–1.00) | 0.84 (0.67–0.95) | 0.76 (0.59–0.88) | 0.96 (0.80–0.99) | 6.20 (2.67–13.59) | 0.07 (0.01–0.47) | 0.88 (0.75–0.95) | |||
| RVS | TVS | 4 (8.2%) | 0 (0.0%) | 43 (87.8%) | 2 (4.1%) | 0.67 (0.22–0.96) | 1.00 (0.92–1.00) | 1.00 (1.00–1.00) | 0.96 (0.87–0.98) | Infinity | 0.33 (0.11–1.03) | 0.96 (0.86–1.00) | 0.125 | |
| MRI | 5 (10.2%) | 3 (6.1%) | 40 (81.6%) | 1 (2%) | 0.83 (0.36–1.00) | 0.93 (0.81–0.99) | 0.63 (0.35–0.84) | 0.98 (0.87–1.00) | 11.9 (3.79–37.67) | 0.18 (0.03–1.07) | 0.92 (0.80–0.98) | |||
| Vagina | TVS | 6 (12.2%) | 0 (0.0%) | 38 (77.6%) | 5 (10.2%) | 0.55 (0.23–0.83) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 0.88 (0.80 –0.94) | Infinity | 0.45 (0.24–0.87) | 0.90 (0.78–0.97) | 0.688 | |
| MRI | 8 (16.3%) | 2 (4.1%) | 36 (73.5%) | 3 (6.1%) | 0.73 (0.39–0.94) | 0.95 (0.82–0.99) | 0.80 (0.50–0.94) | 92.31 (0.82–0.97) | 13.82 (3.42–55.9) | 0.29 (0.11–0.76) | 0.90 (0.78–0.97) | |||
| POD obliteration | TVS | 35 (71.5%) | 1 (2%) | 8 (16.3%) | 5 (10.2%) | 0.88 (0.73–0.96) | 0.89 (0.52–1.00) | 0.97 (0.85–1.00) | 0.62 (0.41–0.79) | 7.87 (1.24–50.16) | 0.14 (0.06–0.33) | 0.88 (0.75–0.95) | 0.040 | |
| MRI | 23 (46.9%) | 5 (10.2%) | 4 (8.2%) | 17 (34.7%) | 0.58 (0.41–0.73) | 0.44 (0.14–0.79) | 0.82 (0.71–0.90) | 0.19 (0.09–0.35) | 1.03 (0.54–1.97) | 0.96 (0.42–2.16) | 0.55 (0.40–0.69) | |||
|
| ||||||||||||||
| Pelvis | Overall pelvic DE | TVS | 80 (20.4%) | 10 (2.5%) | 280 (71.4%) | 22 (5.6%) | 0.78 (0.69–0.86) | 0.97 (0.94–0.98) | 0.89 (0.81–0.94) | 0.93 (0.90–0.95) | 22.8 (12.30–42.20) | 0.22 (0.15–0.32) | 0.92 (0.89–0.94) | |
| MRI | 93 (23.7%) | 25 (6.4%) | 265 (67.6%) | 9 (2.3%) | 0.91 (0.84–0.96) | 0.91 (0.88–0.94) | 0.79 (0.72–0.84) | 0.97 (0.94–0.98) | 10.58 (7.24–15.46) | 0.10 (0.05–0.18) | 0.91 (0.88–0.94) | |||
§At least one affected side correctly identified. Total DE lesions are the sum of all individual sites affected in all participants. CI, confidence intervals; DE, deep endometriosis; FN, false negative; FP, False positive; LR+, positive likelihood ratio; LR−, negative likelihood ratio; MRI, magnetic resonance imaging; NPV, negative predictive value; p-value, probability value of ultrasound vs. MRI performance (<0.05 considered significant); POD, pouch of Douglas; PPV, positive predictive value; RVS, rectovaginal septum; USL, uterosacral ligament; TAS, transabdominal ultrasound scan; TN, true negative TP, true positive; TVS, transvaginal ultrasound scan.
Figure 2Schematic drawings demonstrating the IDEA proposed anatomical definitions of deep pelvic endometriotic lesions [7]: (a) pelvis—transverse plane at the level of cervix; (b) pelvis—longitudinal plane showing bowel and bladder sections, (c) pelvis—longitudinal plane demonstrating vagina and adjacent structures. AC, anterior compartment; BB, bladder base; BD, bladder dome; LP, lateral parametria; LR, lower rectum; PC, posterior compartment; RB, retroperitoneal part of the bladder; R; rectum; RS, rectosigmoid; RVS, rectovaginal septum; S; sigmoid; TB, trigonum (bladder); U; ureter; UR, upper rectum; USL, uterosacral ligament; V; vagina.
Figure 3Nodule of deep endometriosis in the bladder base: (a) schematic drawing in the longitudinal view; (b) transvaginal ultrasound in the longitudinal plane; (c) magnetic resonance imaging in the transverse plane; (d) magnetic resonance imaging in the longitudinal plane; (e) laparoscopic resection; (f) histology. MP, muscularis propria; TVS, transvaginal ultrasound; T2W, T2-weighted magnetic resonance imaging; U; uterus; , deep endometriosis lesion.
Comparison of results with previous research.
| Pelvis | Areas investigated for DE | Index tests | Sensitivity (%) | Specificity (%) | ||
|---|---|---|---|---|---|---|
| This study | Previous literature (author, year) | This study | Previous literature (author, year) | |||
| Anterior compartment | Bladder | TVS | 89.0 | 62.0 (Guerriero, 2015) [ | 100.0 | 100 (Guerriero, 2015) [ |
| 100 (Exacoustos, 2014) [ | 96.8 (Exacoustos, 2014) [ | |||||
| 44.0 (Savelli, 2009) [ | 100 (Savelli, 2009) [ | |||||
| MRI | 100.0 | 64.0 (Medeiros, 2015) [ | 95.0 | 98.0 (Medeiros, 2015) [ | ||
| 81.0 (Krüger, 2013) [ | 94.7 (Krüger, 2013) [ | |||||
|
| ||||||
| Posterior compartment | USL | TVS | 74.0 | 67.0 (Guerriero, 2018) [ | 67.0 | 86.0 (Guerriero, 2018) [ |
| MRI | 94.0 | 70.0 (Guerriero, 2018) [ | 60.0 | 93.0 (Guerriero, 2018) [ | ||
| 85.0 (Medeiros, 2015) [ | 80.0 (Medeiros, 2015) [ | |||||
| 77.5 (Krüger, 2013) [ | 68.2 (Krüger, 2013) [ | |||||
| Right USL | TVS | 56.0 | 80.7 (Exacoustos, 2014) [ | 84.0 | 87.2 (Exacoustos, 2014) [ | |
| MRI | 94.0 | 93.0 (Bazot, 2011) [ | 65.0 | 72.0 (Bazot, 2011) [ | ||
| Left USL | TVS | 81.0 | 82.8 (Exacoustos, 2014) [ | 100.0 | 85.0 (Exacoustos, 2014) [ | |
| MRI | 88.0 | 89.0 (Bazot, 2011) [ | 91.0 | 61.0 (Bazot, 2011) [ | ||
| Rectum lower/upper | TVS | 100.0 | 89.7§ (Exacoustos, 2014) [ | 100.0 | 86.2§ (Exacoustos, 2014) [ | |
| 94.4 | 84.9 | |||||
| MRI | 100.0 | — | 100.0 | — | ||
| Rectosigmoid | TVS | 94.0 | 85.0 (Guerriero, 2018) [ | 84.0 | 96.0 (Guerriero, 2018) [ | |
| MRI | 94.0 | 85.0 (Guerriero, 2018) [ | 84.0 | 95.0 (Guerriero, 2018) [ | ||
| 83.0 (Medeiros,2015) [ | 88.0 (Medeiros, 2015) [ | |||||
| 80.2 (Krüger, 2013) [ | 77.5 (Krüger, 2013) [ | |||||
| RVS | TVS | 67.0 | 59.0 (Guerriero, 2018) [ | 100.0 | 97.0 (Guerriero, 2018) [ | |
| 73.9 (Exacoustos, 2014) [ | 86.2 (Exacoustos, 2014) [ | |||||
| MRI | 83.0 | 66.0 (Guerriero, 2018) [ | 93.0 | 97.0 (Guerriero, 2018) [ | ||
| 77.0 (Medeiros, 2015) [ | 95.0 (Medeiros, 2015) [ | |||||
| Vagina | TVS | 55.0 | 58.6 (Exacoustos, 2014) [ | 100.0 | 82.7 (Exacoustos, 2014) [ | |
| MRI | 73.0 | 82.0 (Medeiros, 2015) [ | 95.0 | 82.0 (Medeiros, 2015) [ | ||
| 81.4 (Krüger, 2013) [ | 81.7 (Krüger, 2013) [ | |||||
§Cranial (upper) rectum. Lower (caudal) rectum. DE, deep endometriosis; USL, uterosacral ligaments; RVS, rectovaginal septum; TVS, transvaginal ultrasound; MRI, magnetic resonance imaging.